Merck & Co., Inc. vs AT&T Inc. — how do they compare? Merck & Co., Inc. trades at $133.12 (market cap $321.77B), while AT&T Inc. trades at $24.28 (market cap $167.88B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and AT&T Inc. pays the higher dividend (4.53%). Which is the better fit depends on your goals.
| MRK | T | |
|---|---|---|
Market Cap | $321.77B | $167.88B |
Sector | Health | Media |
52-Week High | $131.84 | $29.62 |
52-Week Low | $77.60 | $20.49 |
Enterprise Value | $368.53B | $313.20B |
Dividend Yield | 2.61% | 4.53% |
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
AT&T (T) trades at $24.25, up 0.73% today, with a bullish technical signal from moving averages but overbought RSI near 77. The stock shows strong fundamentals with a P/E of 8.09, net income margin of 16.94%, and consistent earnings beats in recent quarters. Recent news highlights fiber expansion and AI partnerships, while cash flow improved to $15.12B in 2025.
Outlook is positive with a consensus price target of $27.69, offering 14% upside, supported by dividend yield near 4.7%. Risks include competition from SpaceX's Starlink and high debt levels. Analysts are mixed with 41% buy ratings, suggesting cautious optimism for value investors seeking income and steady growth.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →